Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease (NCT03664674) | Clinical Trial Compass
CompletedPhase 3
Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease
United States148 participantsStarted 2018-08-27
Plain-language summary
The purpose of this study is to evaluate the effectiveness of OTO-104 for the treatment of Meniere's disease.
Who can participate
Age range18 Years – 85 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Subject has a diagnosis of unilateral Meniere's disease by 1995 American Academy of Otolaryngology - Head and Neck Surgery (AAOHNS) criteria and reports active vertigo for the 2 months prior to the study lead-in period.
* Subject has experienced active vertigo during the lead-in period.
* Subject has documented asymmetric sensorineural hearing loss.
* Subject agrees to maintain their current treatments for Meniere's disease while on-study.
Exclusion Criteria:
* Subject is pregnant or lactating.
* Subject has a history of immunodeficiency disease.
* Subject has a history of significant middle ear or inner ear surgery, or endolymphatic sac surgery in the affected ear.
* Subject has a history of tympanostomy tubes with evidence of perforation or lack of closure.
* Subject has a history of vestibular migraine.
* Subject has used an investigational drug or device in the 3 months prior to screening.
* Subject has previously been randomized to a clinical study of OTO-104.